# Zai Lab Ltd: Form 10-Q for the period ended Jun 30, 2022

- Company: [Zai Lab Ltd](/companies/zlab.md) (CIK 1704292)
- Form: 10-Q
- Filed: 2022-08-09
- Accepted by EDGAR: Aug 9, 2022, 16:44 ET
- Period: 2022-06-30
- Accession: 0001628280-22-021975
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1704292/000162828022021975/zlab-20220630.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1704292/000162828022021975/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-06-30.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Revenue | 3 months, 2022-04-01 to 2022-06-30 | $47.6m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 6 months, 2022-01-01 to 2022-06-30 | $93.7m | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 3 months, 2022-04-01 to 2022-06-30 | $17.4m | us-gaap:CostOfRevenue |
| Cost of revenue | 6 months, 2022-01-01 to 2022-06-30 | $33.1m | us-gaap:CostOfRevenue |
| Research and development | 3 months, 2022-04-01 to 2022-06-30 | $66.1m | us-gaap:ResearchAndDevelopmentExpense |
| Research and development | 6 months, 2022-01-01 to 2022-06-30 | $119.9m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 3 months, 2022-04-01 to 2022-06-30 | $63.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 6 months, 2022-01-01 to 2022-06-30 | $120.4m | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months, 2022-04-01 to 2022-06-30 | −$98.7m | us-gaap:OperatingIncomeLoss |
| Operating income | 6 months, 2022-01-01 to 2022-06-30 | −$178.5m | us-gaap:OperatingIncomeLoss |
| Income tax | 3 months, 2022-04-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 6 months, 2022-01-01 to 2022-06-30 | $0 | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months, 2022-04-01 to 2022-06-30 | −$137.9m | us-gaap:NetIncomeLoss |
| Net income | 6 months, 2022-01-01 to 2022-06-30 | −$220.3m | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months, 2022-04-01 to 2022-06-30 | −$0.14 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 6 months, 2022-01-01 to 2022-06-30 | −$0.23 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months, 2022-04-01 to 2022-06-30 | −$0.14 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 6 months, 2022-01-01 to 2022-06-30 | −$0.23 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months, 2022-04-01 to 2022-06-30 | 957,684,820 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 6 months, 2022-01-01 to 2022-06-30 | 956,603,250 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 6 months, 2022-01-01 to 2022-06-30 | −$132.0m | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 6 months, 2022-01-01 to 2022-06-30 | $13.5m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Cash and equivalents | at 2022-06-30 | $680.8m | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | at 2022-06-30 | $1.34bn | us-gaap:AssetsCurrent |
| Total assets | at 2022-06-30 | $1.42bn | us-gaap:Assets |
| Current liabilities | at 2022-06-30 | $168.9m | us-gaap:LiabilitiesCurrent |
| Total liabilities | at 2022-06-30 | $206.6m | us-gaap:Liabilities |
| Shareholders' equity | at 2022-06-30 | $1.21bn | us-gaap:StockholdersEquity |

## Management's discussion and analysis

As filed, 59,952 characters.

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our 2021 Annual Report and our unaudited condensed consolidated financial statements and the accompanying notes included in “Item 1. Financial Statements” in this Quarterly Report on Form 10-Q.*

### Overview

We are a patient-focused, innovative, commercial-stage, global biopharmaceutical company with a substantial presence in both Greater China and the United States. We are discovering, developing, and commercializing innovative products that target medical conditions with unmet needs affecting patients in Greater China and worldwide, in the areas of oncology, autoimmune disorders, infectious diseases, and neurological disorders. As of August 3, 2022 we have four commercialized products that have received marketing approval in one or more territories in Greater China and twelve programs in late-stage product development.

Since our inception, we have incurred net losses and negative cash flows from our operations. Substantially all of our losses have resulted from funding our research and development programs and general and administrative costs associated with our operations. Developing high quality product candidates requires a significant investment related to our research and development activities over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. Our ability to generate profits and to generate positive cash flow from operations over the next several years depends upon our ability to successfully market our four commercial products - ZEJULA, Optune, QINLOCK, and NUZYRA – and to successfully develop and commercialize our other product candidates. We expect to continue to incur substantial expenses related to our research and development activities. In particular, our licensing and collaboration agreements require us to make upfront payments upon our entry into such agreements and milestone payments upon the achievement of certain development, regulatory, and commercial milestones as well as tiered royalties based on the net sales of the licensed products. These upfront and milestone payments are recorded in our research and development expense. During the six months ended June 30, 2022, we accrued $10.4 million of research and development expense related to the achievement of certain developmental milestones by our partners during the second quarter of 2022. In addition, we expect to incur substantial costs related to the commercialization of our product candidates, in particular during the early launch phase.

Furthermore, as we pursue our strategy of growth and development, we anticipate that our financial results will fluctuate from quarter to quarter based upon the balance between the successful marketing of our commercial products and our significant research and development expenses. We cannot predict whether or when new products or new indications for marketed products will receive regulatory approval or, if any such approval is received, whether we will be able to successfully commercialize such product(s) and whether or when they may become profitable.

### Recent Developments

#### Recent Product Developments

*ZEJULA*. In June 2022, we presented a new prespecified subgroup analysis from the Phase 3 PRIME study for ZEJULA in women in mainland China with ovarian cancer at the 2022 American Society of Clinical Oncology (“ASCO”) Annual Meeting. This analysis examined 384 newly diagnosed stage III or IV ovarian cancer patients enrolled in the PRIME study who experienced a complete response (“CR”) or partial response (“PR”) to first-line platinum-based chemotherapy. In the CR group, the median progression-free survival (“mPFS”) was 29.4 months for niraparib vs 8.3 months for placebo (HR=0.45; 95% CI, 0.32–0.61; P\<0.001); in the PR group, the mPFS was 19.3 months for niraparib versus 8.3 months for placebo (HR=0.45; 95% CI, 0.23–0.86; P=0.014); and the safety profile of niraparib was consistent with previous clinical trials, with no new safety issues identified in this subgroup analysis.

*Optune*. In June 2022, the Company and Novocure announced the EF-31 phase 2 pilot study, evaluating the safety and efficacy of TTFields together with standard-of-care (chemotherapy alone or in combination with trastuzumab for HER2-positive patients) as a first-line treatment in patients with gastric cancer, met its primary endpoint of objective response rate (“ORR”) with supportive signals across secondary endpoints. As of June 30, 2022, Optune has been listed in 50 regional customized commercial health insurance plans guided by provincial or municipal governments (or “supplemental insurance plans”).

*QINLOCK*. As of June 30, 2022, QINLOCK has been listed in 73 supplemental insurance plans since its commercial launch in mainland China in May 2021.

Adagrasib. At the ASCO Annual Meeting in June 2022, our partner Mirati Therapeutics, Inc. (“Mirati”) presented full results from the registration-enabling Phase 2 cohort of the KRYSTAL-1 study evaluating adagrasib in patients with previously treated non-small cell lung cancer (“NSCLC”) harboring a KRASG12C mutation; these results were concurrently published in the New England Journal of Medicine. This presentation included results from a retrospective subgroup analysis from the Phase 2 NSCLC cohort of the KRYSTAL-1 study evaluating adagrasib in patients with KRASG12C-mutated NSCLC and stable, previously treated central nervous system (“CNS”) metastases. The initial clinical results from the Phase 2 registration-enabling study (n=112) showed that the ORR was 43%, the disease control rate (“DCR”) was 80%, the median duration of response (“mDOR”) was 8.5 months (95% confidence interval (“CI”): 6.2 – 13.8), and the mPFS was 6.5 months (95% CI: 4.7 – 8.4). With a January 15, 2022 data cutoff, the median overall survival (“mOS”) was 12.6 months (95% CI: 9.2 – 19.2). With respect to CNS-specific activity in a subset analysis of stable, previously treated CNS metastases (n=33), results revealed an intracranial (“IC”) ORR of 33% (11/33). Mirati also reported updated findings from a pooled analysis from the KRYSTAL-1 study, including the registrational Phase 2 and Phase 1/1b NSCLC cohorts. The initial results of the pooled analysis of KRYSTAL-1 NSCLC cohorts (n=132) showed that the ORR was 44%, the DCR was 81%, the mDOR was 12.5 months, and the mPFS was 6.9 months. With a January 15, 2022 data cutoff, the mOS was 14.1 months.

In June 2022, Mirati also announced the results of a prospective analysis from the Phase 1b cohort of the KRYSTAL-1 study evaluating IC responses of adagrasib in patients with KRASG12C-mutated advanced NSCLC with active and untreated CNS metastases. The results of the CNS-specific activity in active and untreated CNS metastases (n=19) showed an IC ORR of 32% (6/19).

In addition, the Company treated the first patients in Greater China for the global Phase 3 KRYSTAL-10 study of the combination of adagrasib and cetuximab in patients with KRASG12C-mutated advanced colorectal cancer and for the global Phase 3 KRYSTAL-12 study of adagrasib in patients with KRASG12C-mutated advanced NSCLC in June 2022 and July 2022, respectively.

*Bemarituzumab.* Our partner Amgen initiated a Phase 1b/2 study (FORTITUDE-301), evaluating the safety and efficacy of bemarituzumab monotherapy in solid tumors with FGFR2b overexpression. In addition, Amgen reported that the final analysis of the FIGHT study, a Phase 2 randomized, double-blind, controlled study evaluating bemarituzumab and modified FOLFOX6 (mFOLFOX6) in patients with previously untreated advanced gastric and gastroesophageal junction cancer was completed, with results continuing to demonstrate that bemarituzumab + mFOLFOX6 improves the clinical outcome of patients with FGFR2b expressing tumors with no new safety concerns and noting that a greater survival benefit was observed with increasing FGFR2b expression levels.

*Repotrectinib*. In May 2022, our partner Turning Point Therapeutics, Inc. (“Turning Point”) announced that the FDA granted an eighth regulatory designation, and third Breakthrough Therapy Designation (“BTD”), to repotrectinib, for the treatment of patients with ROS1-positive metastatic NSCLC who have been previously treated with one ROS1 TKI and who have not received prior platinum-based chemotherapy. In June 2022, the Center for Drug Evaluation (“CDE”) of the NMPA granted two Breakthrough Therapy Designations for investigational repotrectinib for the treatment of patients with ROS1-positive metastatic NSCLC who have received one prior line of ROS1 TKI and one prior line of platinum-based chemotherapy and for those with ROS1-positive metastatic NSCLC who have received one prior line of ROS1 TKI and no chemotherapy or immunotherapy. The Breakthrough Therapy Designations for repotrectinib were supported by the data from both global and Chinese TKI-pretreated ROS1-positive NSCLC patients enrolled in the Phase 1/2 TRIDENT-1 study.

*CLN-081*. In June 2022, our partner Cullinan Oncology presented updated data from the Phase 1/2a study in NSCLC patients with EGFR exon 20 insertion mutations at the 2022 ASCO Annual Meeting. Of the 39 patients in the 100 mg BID dose group: 16 (41%) had a confirmed PR; the estimated mDOR was greater than 21 months; mPFS was 12 months; and the safety profile of CLN-081 was amenable for long-term treatment.

*BLU-945*. In June 2022, we received a Clinical Trial Application (“CTA”) approval from the NMPA for the BLU-945 monotherapy cohort of the global Phase 1/2 SYMPHONY study in Greater China.

*VYVGART*. In June 2022, efgartigimod was introduced to the Hainan Bo’ao Lecheng International Medical Tourism Pilot Zone, and the first Chinese patient was treated with efgartigimod. In July 2022, the NMPA accepted the Biologics License Application for efgartigimod alfa injection for the treatment of adult patients with generalized myasthenia gravis (“gMG”) in mainland China.

KarXT. In August 2022, our partner Karuna announced positive topline results from its Phase 3 EMERGENT-2 trial evaluating the efficacy, safety, and tolerability of KarXT in adults with schizophrenia. The trial met its primary endpoint, with KarXT demonstrating a statistically significant and clinically meaningful 9.6-point reduction in the Positive and Negative Syndrome Scale (“PANSS”) total score compared to placebo (-21.2 KarXT vs. -11.6 placebo, p\<0.0001) at Week

5 (Cohen’s d effect size of 0.61). KarXT also demonstrated an early and sustained statistically significant reduction of symptoms, as assessed by PANSS total score, starting at Week 2 and maintained such reduction through all timepoints in the trial. The trial also met its key secondary endpoints, demonstrating statistically significant reductions in positive and negative symptoms of schizophrenia, as measured by the PANSS positive, PANSS negative, and PANSS Marder negative subscales. KarXT was generally well tolerated, with a side effect profile substantially consistent with prior trials of KarXT in schizophrenia.

*Simurosertib (CDC7 Inhibitor)*. Based on an extensive review of the data collected from previously completed studies, we have decided to terminate enrollment for the study of simurosertib.

*ZL-1201 (CD47 Inhibitor)*. In July 2022, Zai Lab determined a recommended Phase 2 dose in the ongoing Phase 1 trial. Based on a review of the competitive landscape, Zai Lab has decided to deprioritize ZL-1201 for internal development but will pursue out-licensing opportunities.

#### Recent Business Developments

In May 2022, we completed our engagement of KPMG to be our independent registered public accounting firm for the fiscal year ending December 31, 2022. On May 25, 2022, the Company received the requisite approvals from the Hong Kong Stock Exchange and the Financial Reporting Council of Hong Kong, and on May 31, 2022, the Company and KPMG signed an engagement letter, and the appointment became effective on the same date.

We also completed our voluntary conversion from secondary listing status to primary listing on the Hong Kong Stock Exchange, effective June 27, 2022. The Company’s ordinary shares and ADSs will continue to be traded on the Hong Kong Stock Exchange and Nasdaq, respectively, and remain mutually fungible. Because of our conversion to primary listing in Hong Kong, we are eligible for the Hong Kong Stock Exchange Stock Connect, a channel by which investors in mainland China can invest in stocks traded on the Hong Kong Stock Exchange. Our ordinary shares have been included in the Shenzhen-Hong Kong Stock Connect and Shanghai-Hong Kong Stock Connect programs since June 2022 and July 2022, respectively.

In July 2022, the Board further enhanced our corporate governance by appointing John Diekman to be lead independent director. The Board continues to believe that the Chief Executive Officer is best suited to serve as Chairperson of the Board at this time, including due to her extensive understanding of our business and industry and her ability to identify strategic opportunities, promote the effective execution of strategic initiatives, and facilitate the flow of information between management and the Board. While the roles of Chairperson of the Board and Chief Executive officer are combined, our lead independent director will, among other things, lead meetings of the Board when the Chairperson is not present, serve as liaison between the Chairperson and independent directors, have the authority to call meetings of the independent directors, and, if requested by major shareholders, be available for consultation and direct communication. As a result of Mr. Diekman’s appointment as lead independent director, he stepped down as Chair of the Audit Committee, although he will continue to serve as a member of the Audit Committee. As a result, the Board appointed Scott Morrison to be Chair of the Audit Committee.

Josh Smiley, aged 53, joined the Company as Chief Operating Officer, effective August 1, 2022. Mr. Smiley brings over 26 years of experience working with the biopharmaceutical industry, including experience leading finance, corporate strategy, business development, venture capital, and global business services operations at Eli Lilly and Company. He will report directly to our Chief Executive Officer and will be a key member of our executive committee. He will oversee all aspects of our business, finance, and global operations.

#### Recent Legal and Regulatory Developments

#### Amendment to the Implementation Regulation of the PRC Drug Administration Law

On May 9, 2022, the NMPA published a comprehensive draft of Amendment to the Implementation Regulation of the PRC Drug Administration Law (the “Draft DAL Implementing Regulations”) for public comments. The Draft Amendment introduced changes to the regulatory framework and aimed to codify certain regulatory initiatives implemented by the Chinese government since the promulgation of the current PRC Drug Administration Law in 2019 (the “DAL”).

The Draft DAL Implementing Regulations propose to extend the reach of DAL to offshore development and manufacturing activities of pharmaceutical companies to the extent that the pharmaceutical companies would like to obtain marketing authorizations for their drug products in mainland China. All overseas R&D activities and production activities concerning a drug to be marketed in mainland China and/or already marketed in mainland China should be carried out in compliance with the regulatory requirements specified in applicable Chinese laws, regulations, rules, standards, and specifications.

Patent linkage and regulatory data protection have been included in the Draft DAL Implementing Regulations. The Draft DAL Implementing Regulations propose to grant market exclusivity with a specified period to first-to-market generic drug contributing to the invalidity of relevant drug patent.

#### PRC Anti-Monopoly Law

On June 24, 2022, the Standing Committee of the National People’s Congress published amendments to the PRC Anti-Monopoly Law (the “AML”), which came into effect on August 1, 2022. The amended AML formally implements China’s latest anti-monopoly policies by, among other things, improving regulatory rules for anti-competitive agreements, expressly addressing monopoly issues in the platform economy, and substantially increasing the penalties for violating the law.

The improvements of the regulatory rules for anti-competitive agreements made by the amended AML mainly includes: (i) expressly stipulating that an agreement which fixes or limits resale prices, that is, a vertical anti-competitive agreement, is not prohibited if relevant business operators can prove that such agreement does not have the effect of eliminating or restricting competition; (ii) formally provides the “safe harbor” regime which stipulates that a vertical anti-competitive agreement is not prohibited, if the parties’ market share in the relevant market is lower than the market share percentage set by the anti-monopoly enforcement agency and other conditions established by the anti-monopoly enforcement agency are met; (iii) codifies that business operators shall not organize other business operators to reach a monopoly agreement or provide substantial assistance for other business operators to reach a monopoly agreement.

The amended AML formally extends the anti-monopoly regulatory regime to the platform economy by outlining the general principal that business operators shall not engage in monopolistic activities, such as by taking advantage of data and algorithms, technology, capital advantage, and platform rules. The amended AML also specifically prohibits business operators from abusing market dominance, such as by using data and algorithms, technology, and platform rules.

Penalties for violation of the AML have been substantially increased by the amended AML. For example, according to the amended AML, if a company completes a concentration of business in violation of the AML that will have or is likely to have the effect of eliminating or restricting competition, in addition to other remedial measures, a fine of up to 10% of the last year’s sales revenue may be imposed. If the concentration of business in violation of the AML completed by the company does not have the effect of eliminating or restricting competition, a fine of up to RMB 5 million may be imposed. In the case that the aforementioned violation has particularly serious circumstances, bad impact, or consequences, the fine imposed may be further increased to between two and five times the aforementioned fine amount.

#### Cross-Border Data Transfers

#### Measures on Security Assessment of Cross-Border Data Transfer

On July 7, 2022, the Cyberspace Administration of China (“CAC”) issued Measures on Security Assessment of Cross-Border Data Transfer (the “Security Assessment Measures”), which sets out a security assessment framework for cross-border data transfers out of mainland China as well as ground rules for a security assessment filing for cross-border data transfers which was stipulated in the Cybersecurity Law (“CSL”) and the Personal Information Protection Law (“PIPL”).

A security assessment will be triggered if a cross-border data transfer out of mainland China falls into any of the following scenarios: (i) transfer of important data by data processors; (ii) transfer of personal information (“PI”) by critical information infrastructure operators (“CIIOs”) and data processors that process PI of more than one million individuals; (iii) transfer of PI by data processors that have transferred either PI of over 100,000 individuals or sensitive PI of over 10,000 individuals abroad since January 1 of the preceding year; and (iv) other situations as determined by the CAC. According to statements by the CAC, a cross-border data transfer includes (i) an outbound transfer and overseas storage of data collected and generated during a data processor’s operation in mainland China; and (ii) a remote access or use of data collected and generated by a data processor stored within mainland China by overseas institutions, organizations, and individuals.

Prior to applying for a security assessment with the CAC, data processors are required to carry out a self-risk assessment, which needs to be presented to the CAC along with an application filing and other required materials for a security assessment. During a security assessment, the CAC will primarily focus on risks to national security, public interests, and the legitimate rights and interests of individuals or organizations that such cross-border data transfer may cause. A cross-border data transfer of relevant data will not be allowed if the CAC does not approve the security assessment filing. Once the CAC approves the security assessment filing, such approval will remain valid for two years and may be renewed. An application for security assessment needs to be re-submitted if there is a change in the cross-border data transfer that may affect the security of the exported data, such as changes in the purpose, method, scope, and type of the exported data and changes in the purpose and method of the processing of the exported data by overseas recipients.

The Security Assessment Measures have retroactive effect for cross-border data transfers out of mainland China of relevant data conducted prior to their effective date on September 1, 2022. If a Data Processor fails to complete its security assessment for any of its cross-border data transfers of relevant data out of mainland China prior to the effective date of the Security Assessment Measures, it needs to rectify the failure within six months after the effective date of the Security Assessment Measures.

#### Specification for Certification of Personal Information Cross-Border Processing Activities

On June 24, 2022, the National Information Security Standardization Technical Committee issued Guidance on Network Security Standardized Practice – Specification for Certification of Personal Information Cross-Border Processing Activities (the “Certification Specification”), which serves as an industry standard. The Certification Specification provides that PI processors may apply for a personal information protection certification (a “PIPC”) from certain qualified institutions, pursuant to which PI processors, provided that the requirements stipulated by PIPL are met, may rely on a PIPC to comply with cross-border PI transfer requirements when engaging in (i) intra-group cross-border transfers within a multinational company or subsidiaries or affiliated companies of an economic / business entity, or (ii) data processing activities conducted outside of mainland China involving PI of individuals located in mainland China subject to the extra-territorial jurisdiction of the PIPL.

The PI processors involved in PI cross-border activities shall carry out a prior self-risk assessment focusing on whether the cross-border PI transfer is legitimate, justifiable, and necessary and the security protection measures taken are effective and appropriate to the degree of risks. A self-risk assessment must include the following factors: (i) whether the cross-border PI transfer complies with applicable laws and administrative regulations; (ii) the impact on the rights and interests of PI subjects, particularly the impact of the legal environment and network security environment of the foreign countries and regions; and (iii) other matters necessary to safeguard the rights and interests in relation to PI.

The list of qualified institutions for PIPC has not been released to date, and therefore, it is not yet possible for companies to rely on a PIPC to legitimize their cross-border data transfers.

#### Standard Contract for Cross-Border PI Transfer and Accompanying Regulations

On June 30, 2022, the CAC issued for public consultation draft Regulations on the Standard Contract for Cross-Border Transfer of Personal Information, which introduced a draft standard contract for the cross-border transfer of PI outside of mainland China (the “PRC SC”). The PRC SC clarifies terms and conditions to be agreed on between PI processors as a data exporter and an overseas recipient as a data importer with respect to cross-border data transfers of PI out of mainland China. When finalized, the PRC SC can be used to comply with requirements under the PIPL for cross-border data transfers of PI out of mainland China that do not need to undergo a security assessment.

When finalized, a PI processor may enter into the PRC SC and provide it along with other required materials to relevant governmental authorities for filing to ensure the legality of a cross-border transfer out of mainland China if the following conditions are satisfied: the PI processor (i) is not a CIIO; (ii) processes PI of fewer than 1 million individuals; (iii) has provided PI of fewer than 100,000 individuals overseas in aggregate since January 1 of the preceding year; and (iv) has provided sensitive PI of fewer than 10,000 individuals overseas in aggregate since January 1 of the preceding year.

The PRC SC imposes certain obligations on the parties of such cross-border PI transfers to protect the interests of PI subjects, including, for example, (i) data exporters are required to use reasonable efforts to ensure data importers have adequate technical and organizational measures to ensure secure processing and have relevant capabilities to fulfill their obligations relating to the data transfer, and (ii) the parties of such cross-border transfer are required to ensure that the rights and interests of data subjects are well recognized in practice (and data subjects’ inquiries are promptly responded to), as such data subjects are considered third-party beneficiaries of the PRC SC.

### Factors Affecting our Results of Operations

### Research and Development Expenses

We believe our ability to successfully develop product candidates will be the primary factor affecting our long-term competitiveness, as well as our future growth and development. Developing high quality product candidates requires a significant investment of resources over a prolonged period of time, and a core part of our strategy is to continue making sustained investments in this area. As a result of this commitment, our pipeline of product candidates has been advancing and expanding, with twelve late-stage clinical product candidates being investigated as of June 30, 2022.

We have financed our activities primarily through private placements, our initial public offering on Nasdaq in September 2017, multiple follow-on offerings, and a secondary listing on the Hong Kong Stock Exchange in September 2020. Through June 30, 2022, we have raised approximately $164.6 million from private equity financing and approximately $2,462.7 million in net proceeds after deducting underwriting commissions and the offering expenses payable by us from our initial public offering, follow-on offerings, and secondary listing. Our operations have consumed substantial amounts of cash since inception. The net cash used in our operating activities was $132.0 million and $235.3 million for the six months ended June 30, 2022 and 2021, respectively. We expect our expenditures to increase significantly in connection with our ongoing activities, particularly as we advance the clinical development of our twelve late-stage clinical product candidates, research and develop our clinical- and pre-clinical-stage product candidates, and initiate additional clinical trials of, and seek regulatory approval for, these and other future product candidates. We review such expenditures for prioritization and efficiency purposes. These expenditures include:

- expenses incurred for contract research organizations (CROs), contract manufacture organizations (CMOs), investigators and clinical trial sites that conduct our clinical studies;
- employee compensation related expenses, including salaries, benefits and equity compensation expenses;
- expenses for licensors;
- the cost of acquiring, developing and manufacturing clinical study materials;
- facilities and other expenses, which include office leases and other overhead expenses;
- costs associated with pre-clinical activities and regulatory operations;
- expenses associated with the construction and maintenance of our manufacturing facilities; and
- costs associated with operating as a public company.

The Company is in the process of evaluating its development programs and is developing a series of recommendations for prioritizing these programs to concentrate our resources on programs that have the greatest potential to beneficially impact patients, strengthen our global competitiveness, and provide long-term sustainability.

### Selling, General, and Administrative Expenses

Our selling, general, and administrative expenses consist primarily of personnel compensation and related costs, including share-based compensation for commercial and administrative personnel. Other selling, general, and administrative expenses include product distribution and promotion costs, professional service fees for legal, intellectual property, consulting, auditing, and tax services as well as other direct and allocated expenses for rent and maintenance of facilities, insurance, and other supplies used in selling, general, and administrative activities. We anticipate that our selling, general, and administrative expenses will increase in future periods to support increases in our commercial and research and development activities and as we continue to commercialize, develop, and manufacture our products and assets. These increases will likely include increased headcount, increased share-based compensation charges, increased product distribution and promotion costs, expanded infrastructure, and increased costs for insurance. We also anticipate incurring additional legal, compliance, accounting, and investor and public relations expenses associated with being a public company.

### Our Ability to Commercialize Our Product Candidates

As of June 30, 2022, twelve of our product candidates are in late-stage clinical development and various others are in clinical and pre-clinical development in Greater China and the United States. Our ability to generate revenue from our product candidates is dependent on our receipt of regulatory approvals for and successful commercialization of such products, which may never occur. Certain of our product candidates may require additional pre-clinical and/or clinical development, regulatory approvals in multiple jurisdictions, manufacturing supply, substantial investment and significant marketing efforts before we generate any revenue from product sales.

### Our License Arrangements

Our results of operations have been, and we expect them to continue to be, affected by our licensing, collaboration and development agreements. We are required to make upfront payments upon our entry into such agreements and milestone payments upon the achievement of certain development, regulatory, and commercial milestones for the relevant products under these agreements as well as tiered royalties based on the net sales of the licensed products. These accruals for upfront and milestone payments are recorded in research and development expense and were $10.4 million for the three and six months ended June 30, 2022 and $98.0 million and $269.2 million for the three and six months ended June 30, 2021, respectively.

### Results of Operations

The following table summarizes our results of operations for the three and six months ended June 30, 2022 and 2021 (in thousands, except percentages):

| Revenues: | Three Months Ended June 30, 2022 | 2021 | Change $% |  | Six Months Ended June 30, 2022 | 2021 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Product revenue, net | 47,575 | 36,935 | 10,640 | 29% | 93,670 | 57,038 | 36,632 | 64% |
| Collaboration revenue | 601 | — | 601 | 100% | 1,230 | — | 1,230 | 100% |
| Total revenues | 48,176 | 36,935 | 11,241 | 30% | 94,900 | 57,038 | 37,862 | 66% |
| Expenses: |  |  |  |  |  |  |  |  |
| Cost of sales | (17,407) | (10,868) | (6,539) | 60% | (33,051) | (18,373) | (14,678) | 80% |
| Research and development | (66,084) | (142,224) | 76,140 | (54)% | (119,938) | (346,076) | 226,138 | (65)% |
| Selling, general, and administrative | (63,401) | (54,414) | (8,987) | 17% | (120,392) | (90,252) | (30,140) | 33% |
| Loss from operations | (98,716) | (170,571) | 71,855 | (42)% | (178,481) | (397,663) | 219,182 | (55)% |
| Interest income | 1,175 | 244 | 931 | 382% | 1,363 | 458 | 905 | 198% |
| Other income (expenses), net | (40,392) | 7,406 | (47,798) | (645)% | (42,988) | 1,179 | (44,167) | (3746)% |
| Loss before income tax and share of loss from equity method investment | (137,933) | (162,921) | 24,988 | (15)% | (220,106) | (396,026) | 175,920 | (44)% |
| Income tax expense | — | — | — | —% | — | — | — | —% |
| Share of loss from equity method investment | — | (403) | 403 | (100)% | (221) | (208) | (13) | 6% |
| Net loss | (137,933) | (163,324) | 25,391 | (16)% | (220,327) | (396,234) | 175,907 | (44)% |
| Net loss attributable to ordinary shareholders | (137,933) | (163,324) | 25,391 | (16)% | (220,327) | (396,234) | 175,907 | (44)% |

### Revenues

### Product Revenue, net

Our product revenue is primarily derived from the sales of ZEJULA, Optune, QINLOCK, and NUZYRA in mainland China and Hong Kong. Sales rebates are offered to distributors in mainland China and the amounts are recorded as a reduction of revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories.

The Company lowered the selling price of ZEJULA due to its inclusion in the NRDL in December 2020 and December 2021 for certain therapies. Accordingly, the Company accrued $0.3 million and $2.9 million of sales rebates as compensation to distributors for those products previously sold at the price prior to the NRDL implementation during the three and six months ended June 30, 2022, respectively, and nil and $22.0 million during the three and six months ended June 30, 2021, respectively.

QINLOCK and NUZYRA are also scheduled to enter negotiations with the National Healthcare Security Administration regarding potential inclusion in the NRDL, and in June 2022, the Company lowered the selling price for these products. Accordingly, the Company accrued $2.7 million and $0.2 million for sales rebates as compensation to distributors previously sold at the price prior to the reduction during the three months ended June 30, 2022 for QINLOCK and NUZYRA, respectively.

In addition, between March 2022 and May 2022, a number of government restrictions or lockdown measures were imposed in Greater China to help control the spread of COVID-19, including in some large cities like Shanghai. These government restrictions or lockdown measures caused some patients to have limited or no access to ZEJULA, Optune, QINLOCK, or NUZYRA, which had a negative impact on our revenue. Although the revenue impact was modest in the second quarter of 2022, we expect some residual revenue impacts in the second half of 2022. For more information on risks related to the COVID-19 pandemic, see “Item 1A. Risk Factors.”

The following table presents net revenue by product for the three and six months ended June 30, 2022 and 2021(in thousands, except percentages):

|  | Three Months Ended June 30, 2022 | 2021 | Change $% |  | Six Months Ended June 30, 2022 | 2021 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| ZEJULA | 34,052 | 23,366 | 10,686 | 46% | 63,649 | 35,972 | 27,677 | 77% |
| Optune | 11,592 | 9,535 | 2,057 | 22% | 24,389 | 16,665 | 7,724 | 46% |
| QINLOCK | 623 | 4,034 | (3,411) | (85)% | 3,582 | 4,401 | (819) | (19)% |
| NUZYRA | 1,308 | — | 1,308 | —% | 2,050 | — | 2,050 | —% |
| Total product revenue, net | 47,575 | 36,935 | 10,640 | 29% | 93,670 | 57,038 | 36,632 | 64% |

25

### Collaboration revenue

Collaboration revenue increased by $0.6 million to $0.6 million for the three months ended June 30, 2022 from nil for the three months ended June 30, 2021. Collaboration revenue increased by $1.2 million for the six months ended June 30, 2022 from nil for the six months ended June 30, 2021. These increases were due to our collaborative arrangement with Huizheng (Shanghai) Pharmaceutical Technology Co., Ltd.

### Cost of Sales

Cost of sales increased by $6.5 million to $17.4 million for the three months ended June 30, 2022 from $10.9 million for the three months ended June 30, 2021, and increased by $14.7 million to $33.1 million for the six months ended June 30, 2022 from $18.4 million for the six months ended June 30, 2021. These increases were primarily due to increasing sales volume, higher product costs, and higher royalties.

### Research and Development Expenses

The following table sets forth the components of our research and development expenses for the three and six months ended June 30, 2022 and 2021 (in thousands, except percentages):

| Research and development expenses: | Three Months Ended June 30, 2022 | 2021 | Change $% |  | Six Months Ended June 30, 2022 | 2021 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Personnel compensation and related costs | $27,045 | $17,282 | $9,763 | 56% | $51,847 | $29,979 | $21,868 | 73% |
| Licensing fees | 10,436 | 97,966 | (87,530) | (89)% | 10,436 | 269,248 | (258,812) | (96)% |
| CROs/CMOs/Investigators expenses | 23,368 | 19,618 | 3,750 | 19% | 46,918 | 35,144 | 11,774 | 34% |
| Other costs | 5,235 | 7,358 | (2,123) | (29)% | 10,737 | 11,705 | (968) | (8)% |
| **Total** | $66,084 | $142,224 | $(76,140) | (54)% | $119,938 | $346,076 | $(226,138) | (65)% |

Research and development expenses decreased by $76.1 million to $66.1 million for the three months ended June 30, 2022 from $142.2 million for the three months ended June 30, 2021 primarily due to:

- a decrease of $87.5 million in licensing fees as we recorded no upfront payments for licensing agreements; partially offset by
- an increase of $9.8 million in personnel compensation and related costs primarily attributable to increased employee compensation costs due to headcount growth and the grants of new share options and restricted shares and the continued vesting of those awards during the three months ended June 30, 2022;
- an increase of $3.8 million in CROs/CMOs/Investigators expenses related to ongoing and newly initiated clinical trials in the three months ended June 30, 2022.

Research and development expenses decreased by $226.1 million to $119.9 million for the six months ended June 30, 2022 from $346.1 million for the six months ended June 30, 2021 primarily due to:

- a decrease of $258.8 million in licensing fees as we recorded no upfront payments for licensing agreements; partially offset by
- an increase of $21.9 million in personnel compensation and related costs primarily attributable to increased employee compensation costs due to headcount growth and the grants of new share options and restricted shares and the continued vesting of those awards during the six months ended June 30, 2022;
- an increase of $11.8 million in CROs/CMOs/Investigators expenses related to ongoing and newly initiated clinical trials in the six months ended June 30, 2022.

The following table summarizes our research and development expenses by program for the three and six months ended June 30, 2022 and 2021 (in thousands, except percentages):

| Research and development expenses: | Three Months Ended June 30, 2022 | 2021 | Change $% |  | Six Months Ended June 30, 2022 | 2021 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Clinical programs | $33,292 | $93,433 | $(60,141) | (64)% | $56,144 | $279,689 | $(223,545) | (80)% |
| Pre-clinical programs | 1,657 | 28,545 | (26,888) | (94)% | 4,222 | 31,045 | (26,823) | (86)% |
| Unallocated research and development expenses | 30,835 | 20,246 | 10,589 | 52% | 59,272 | 35,342 | 23,930 | 68% |
| **Total** | $65,784 | $142,224 | $(76,440) | (54)% | $119,638 | $346,076 | $(226,438) | (65)% |

Research and development expenses attributable to clinical programs decreased by $60.1 million to $33.3 million for the three months ended June 30, 2022 from $93.4 million during the three months ended June 30, 2021. Research and development expenses attributable to pre-clinical programs decreased by $26.9 million to $1.7 million for the three months ended June 30, 2022 from $28.5 million during the three months ended June 30, 2021. Those decreases were driven by decreased license fees.

Research and development expenses attributable to clinical programs decreased by $223.5 million to $56.1 million for the six months ended June 30, 2022 from $279.7 million during the six months ended June 30, 2021. Research and development expenses attributable to pre-clinical programs decreased by $26.8 million to $4.2 million for the six months ended June 30, 2022 from $31.0 million during the six months ended June 30, 2021. Those decreases were driven by decreased license fees.

Although we manage our external research and development expenses by program, we do not allocate our internal research and development expenses by program because our employees and internal resources may be engaged in projects for multiple programs at any given time.

### Selling, General, and Administrative Expenses

The following table summarizes our selling, general and administrative expenses by program for the three and six months ended June 30, 2022 and 2021 (in thousands, except percentages):

| Selling, General and Administrative Expenses: | Three Months Ended June 30, 2022 | 2021 | Change $% |  | Six Months Ended June 30, 2022 | 2021 | Change $% |  |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Personnel compensation and related costs | $41,320 | $30,060 | $11,260 | 37% | $79,523 | $53,472 | $26,051 | 49% |
| Professional service fees | 8,072 | 4,806 | 3,266 | 68% | 15,505 | 8,389 | 7,116 | 85% |
| Other costs | 14,009 | 19,548 | (5,539) | (28)% | 25,364 | 28,391 | (3,027) | (11)% |
| **Total** | $63,401 | $54,414 | $8,987 | 17% | $120,392 | $90,252 | $30,140 | 33% |

Selling, general, and administrative expenses increased by $9.0 million to $63.4 million for the three months ended June 30, 2022 from $54.4 million for the three months ended June 30, 2021 primarily due to:

- an increase of $11.3 million in personnel compensation and related costs which was primarily attributable to increased commercial and administrative personnel costs due to headcount growth and grants of new share options and restricted shares and the continued vesting of those awards during the three months ended June 30, 2022;
- an increase of $3.3 million in professional service fees mainly attributable to our increased legal, compliance, accounting, and investor and public relations expenses associated with being a public company and in connection with sales of ZEJULA, Optune, QINLOCK, and NUZYRA in mainland China and Hong Kong after our commercial launch of these four commercialized products; those increases were partially offset by
- a decrease of $5.5 million in other costs mainly related to selling, rental, and administrative expenses for commercial operations in mainland China, Hong Kong, and Taiwan.

Selling, general, and administrative expenses increased by $30.1 million to $120.4 million for the six months ended June 30, 2022 from $90.3 million for the six months ended June 30, 2021 primarily due to:

- an increase of $26.1 million in personnel compensation and related costs which was primarily attributable to increased commercial and administrative personnel costs due to headcount growth and grants of new share options and restricted shares and the continued vesting of those awards during the six months ended June 30, 2022;
- an increase of $7.1 million in professional service fees mainly attributable to our increased legal, compliance, accounting, and investor and public relations expenses associated with being a public company and in connection with sales of ZEJULA, Optune, QINLOCK, and NUZYRA in mainland China and Hong Kong after our commercial launch of these four commercialized products; those increases were partially offset by
- a decrease of $3.0 million in other costs mainly related to selling, rental, and administrative expenses primarily for the commercial operation in mainland China, Hong Kong, and Taiwan.

### Interest Income

Interest income was $1.2 million and $0.2 million for the three months ended June 30, 2022 and 2021, respectively, and $1.4 million and $0.5 million for the six months ended June 30, 2022 and 2021, respectively.

### Other Income (Expenses), Net

Other income (expenses), net decreased by $47.8 million to $40.4 million of net expense for the three months ended June 30, 2022 from $7.4 million of net income for the three months ended June 30, 2021 primarily as a result of an increase in foreign exchange loss of $42.2 million and an equity investment loss in MacroGenics of $5.6 million.

Other income (expenses), net decreased by $44.2 million to $43.0 million of net expense for the six months ended June 30, 2022 from $1.2 million of net income for the six months ended June 30, 2021 primarily as a result of an increase in foreign exchange loss of $33.5 million and an equity investment loss in MacroGenics of $12.6 million, partially offset by an increase in governmental subsidies of $1.5 million.

### Critical Accounting Policies and Significant Judgments and Estimates

We prepare our financial statements in conformity with U.S. GAAP, which requires us to make judgments, estimates, and assumptions. We periodically evaluate these judgments, estimates, and assumptions based on the most recently available information, our own historical experiences, and various other assumptions that we believe to be reasonable under the circumstances. Since the use of estimates is an integral component of the financial reporting process, actual results could differ from our expectations as a result of changes in our estimates. Some of our accounting policies require a higher degree of judgment than others in their application and require us to make significant accounting estimates.

The selection of critical accounting policies, the judgments and other uncertainties affecting application of those policies and the sensitivity of reported results to changes in conditions and assumptions are factors that should be considered when reviewing our financial statements. We believe the following accounting policies involve the most significant judgments and estimates used in the preparation of our financial statements.

### Revenue recognition

#### Description

In mainland China, we sell our products to distributors, who ultimately sell the products to healthcare providers. Based on the nature of the arrangements, the performance obligations are satisfied upon the product’s delivery to distributors.

#### Judgments and Uncertainties

Rebates are offered to distributors, consistent with pharmaceutical industry practices. The estimated amount of unpaid or unbilled rebates, if any, is recorded as a reduction of revenue. Estimated rebates are determined based on contracted rates, sales volumes, and level of distributor inventories. We regularly review the information related to these estimates and adjust the amount accordingly.

#### Sensitivity of Estimate to Change

Actual amounts of rebates ultimately paid or billed may differ from our estimates. We will reassess estimates for rebates periodically. If actual results in the future vary from our estimates, we will adjust these estimates, which would affect net product revenue and earnings in the period such variances become known.

### Research and Development Expenses

#### Description

Research and development expenses are charged to expense as incurred when these expenditures relate to our research and development services and have no alternative future uses.

Pre-clinical and clinical trial costs are a significant component of our research and development expenses. We have a history of contracting with third parties that perform various pre-clinical and clinical trial activities on our behalf in the ongoing development of our product candidates. Expenses related to pre-clinical and clinical trials are accrued based on our estimates of the actual services performed by the third parties for the respective period.

#### Judgments and Uncertainties

The process of estimating our research and development expenses involves reviewing open contracts and purchase orders, communicating with our personnel to identify services that have been performed on our behalf, and estimating the level of service performed and the associated costs incurred for the services when we have not yet been invoiced or otherwise notified of the actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advanced payments. We make estimates of our expenses as of each balance sheet date in our financial statements based on facts and circumstances known to us at that time.

#### Sensitivity of Estimate to Change

Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in us reporting expenses that are too high or too low in any particular period. To date, we have not made any material adjustments to our prior estimates of research and development expenses.

### Share-Based Compensation

#### Description

Share-based awards for our employees are measured at the grant date fair value of the awards and recognized as expenses (1) immediately at grant date if no vesting conditions are required; or (2) using graded vesting method over the requisite service period, which is the vesting period.

To the extent the required vesting conditions are not met resulting in the forfeiture of the share-based awards, previously recognized compensation expenses relating to those awards are reversed.

#### Judgments and Uncertainties

We determine the fair value of the stock options granted to employees using the Black-Scholes option valuation model. Using this model, fair value is calculated based on assumptions with respect to (i) the expected volatility of our ADS price, (ii) the periods of time over which grantees are expected to hold their options prior to exercise (expected lives), (iii) the expected dividend yield on our ADSs, and (iv) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the expected lives of the options. Expected volatility has been estimated based on actual movements in the stock prices of certain comparable companies over the most recent historical periods equivalent to the options’ expected lives. Expected lives are principally based on our historical exercise experience with previous option grants. The expected dividend yield is zero as we have never paid dividends and do not currently anticipate paying any in the foreseeable future.

#### Sensitivity of Estimate to Change

The assumptions used in this method to determine the fair value of our ordinary shares consider historical trends, macroeconomic conditions, and projections consistent with the Company’s operating strategy. Changes in these estimates can have a significant impact on the determination of fair value of the stock options. If factors change or different assumptions are used, our share-based compensation expenses could be materially different for any period.

### Income Taxes

#### Description

In accordance with the provisions of ASC 740, Income Taxes, we recognize in our financial statements the benefit of a tax position if the tax position is “more likely than not” to prevail based on the facts and technical merits of the position. Tax positions that meet the “more likely than not” recognition threshold are measured at the largest amount of tax benefit that has a greater than fifty percent likelihood of being realized upon settlement. We estimate our liability for unrecognized tax benefits which are periodically assessed and may be affected by changing interpretations of laws, rulings by tax authorities, changes and/or developments with respect to tax audits, and expiration of the statute of limitations. The ultimate outcome for a particular tax position may not be determined with certainty prior to the conclusion of a tax audit and, in some cases, appeal or litigation process.

#### Judgments and Uncertainties

We consider positive and negative evidence when determining whether some portion or all of our deferred tax assets will not be realized. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carry-forward periods, our historical results of operations and our tax planning strategies. The ultimate realization of deferred tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Based upon the level of our historical taxable income and projections for future taxable income over the periods in which the deferred tax assets are deductible, we believe it is more likely than not that we will not realize the deferred tax assets resulted from the tax loss carried forward in the future periods.

#### Sensitivity of Estimate to Change

The actual benefits ultimately realized may differ from our estimates. As each audit is concluded, adjustments, if any, are recorded in our financial statements in the period in which the audit is concluded. Additionally, in future periods, changes in facts, circumstances and new information may require us to adjust the recognition and measurement estimates with regard to individual tax positions. Changes in recognition and measurement estimates are recognized in the period in which the changes occur. As of June 30, 2022 and 2021, we did not have any significant unrecognized uncertain tax positions.

### B. Liquidity and Capital Resources

We have financed our activities primarily through private placements, our September 2017 initial public offering on Nasdaq, various follow-on offerings and our September 2020 secondary listing on the Hong Kong Stock Exchange of our ordinary shares and/or ADSs. Through June 30, 2022, we have raised approximately $164.6 million from private equity financing and approximately $2,462.7 million in net proceeds after deducting underwriting commissions and the offering expenses payable by us from our initial public offering, secondary listing and subsequent follow-on offerings.

Our operations have consumed substantial amounts of cash since inception. The net cash used in our operating activities was $132.0 million and $235.3 million for the six months ended June 30, 2022 and 2021, respectively. We have commitments for capital expenditure of $19.5 million as of June 30, 2022, mainly for the purpose of plant construction and installation. We currently are not aware of any events that are reasonably likely to cause a material change in the relationship between our costs and revenues.

As of June 30, 2022, we had cash, cash equivalents, restricted cash and short-term investment of $1,256.9 million. Our expenditures are principally focused on research and development and are largely discretionary. Based on our current operating plan, we expect that our cash, cash equivalents, restricted cash and short-term investments will enable us to fund our operating expenses and capital expenditures requirements for at least the next 12 months. However, in order to bring to fruition our research and development objectives, we will ultimately need additional funding sources and there can be no assurances that they will be made available.

The following table provides information regarding our cash flows for the six months ended June 30, 2022 and 2021 (in thousands):

|  | Six Months Ended June 30, 2022 | 2021 | Change $ |
| --- | ---: | ---: | ---: |
| Net cash used in operating activities | $(132,027) | $(235,348) | $103,321 |
| Net cash (used in) provided by investing activities | (143,869) | 737,828 | (881,697) |
| Net cash (used in) provided by financing activities | (2,240) | 820,949 | (823,189) |
| Effect of foreign exchange rate changes on cash, cash equivalents and restricted cash | (5,144) | 1,028 | (6,172) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | $(283,280) | $1,324,457 | $(1,607,737) |

### Net cash used in operating activities

During the six months ended June 30, 2022, our operating activities used $132.0 million of cash, which resulted principally from our net loss of $220.3 million, adjusted for non-cash charges of $45.9 million, and cash used in our operating assets and liabilities of $42.4 million.

During the six months ended June 30, 2021, our operating activities used $235.3 million of cash, which resulted principally from our net loss of $396.2 million, adjusted for non-cash charges of $85.9 million, and cash provided in our operating assets and liabilities of $75.0 million.

### Net cash (used in) provided by investing activities

Net cash used in investing activities was $143.9 million for the six months ended June 30, 2022 compared to net cash provided by investing activities of $737.8 million for the six months ended June 30, 2021. The shift from cash provided by to cash used in investing activities was primarily due to a decrease of $613.9 million in proceeds from the maturity of short-term investments, an increase of $260.3 million in purchases of short-term investments, and an increase of $7.8 million from purchases of property and equipment during the six months ended June 30, 2022 compared to the six months ended June 30, 2021

### Net cash (used in) provided by financing activities

Net cash used by financing activities was $2.2 million for the six months ended June 30, 2022 compared to net cash provided by financing activities of $820.9 million for the six months ended June 30, 2021. The shift from cash provided by to cash used in financing activities was primarily because we had proceeds of $818.9 million from our issuance of ordinary shares upon public offerings during the six months ended June 30, 2021 while there were no such transactions during the six months ended June 30, 2022.

### C. Research and Development Activities and Expenditures, Including Patents and Licenses

Full details of our research and development activities and expenditures are provided in the “Research and Development Expenses” and “Results of Operations” sections above.

### D. Trend Information

Other than as described elsewhere in this Quarterly Report on Form 10-Q, we are not aware of any trends, uncertainties, demands, commitments or events that are reasonably likely to have a material adverse effect on our revenue, income from continuing operations, profitability, liquidity or capital resources, or that would cause our reported financial information not necessarily to be indicative of future operation results or financial condition.

### Recently Issued Accounting Standards

For more information regarding recently issued accounting standards, please see “Item 8. Financial Statements and Supplementary Data-Recent accounting pronouncements” in our 2021 Annual Report.

## Market risk

As filed, 6,676 characters.

We are exposed to market risk including foreign exchange risk, credit risk, cash flow interest rate risk, and liquidity risk.

### Foreign Exchange Risk

Renminbi, or RMB, is not a freely convertible currency. The State Administration of Foreign Exchange, under the authority of the People’s Bank of China (“PBOC”), controls the conversion of RMB into foreign currencies. The value of RMB is subject to changes in central government policies and to international economic and political developments affecting supply and demand in the China Foreign Exchange Trading System market. The cash and cash equivalents of the Company included aggregated amounts of RMB 425.2 million and RMB151.7 million, which were denominated in RMB, representing 9% and 2% of the cash and cash equivalents, as of June 30, 2022 and December 31, 2021, respectively.

Our business mainly operates in mainland China with a significant portion of our transactions settled in RMB, and our financial statements are presented in U.S. dollars. We do not believe that we currently have significant direct foreign exchange risk and have not used derivative financial instruments to hedge our exposure to such risk. Although, in general, our exposure to foreign exchange risks should be limited, the value of your investment in our ADSs will be affected by the exchange rate between the U.S. dollar and the RMB because the value of our business is effectively denominated in RMB, while ADSs will be traded in U.S. dollars.

The value of the RMB against the U.S. dollar and other currencies may fluctuate and is affected by, among other things, changes in Greater China’s political and economic conditions. The conversion of RMB into foreign currencies, including U.S. dollars, has been based on rates set by the PBOC. On July 21, 2005, the Chinese government changed its decade-old policy of pegging the value of the RMB to the U.S. dollar. Under the revised policy, the RMB is permitted to fluctuate within a narrow and managed band against a basket of certain foreign currencies. This change in policy resulted in a more than 20% appreciation of the RMB against the U.S. dollar in the following three years. Between July 2008 and June 2010, this appreciation halted, and the exchange rate between the RMB and U.S. dollar remained within a narrow band. In June 2010, the PBOC announced that Chinese government would increase the flexibility of the exchange rate, and thereafter allowed the RMB to appreciate slowly against the U.S. dollar within the narrow band fixed by the PBOC. However, in August 2015, the PBOC significantly devalued the RMB.

The value of our ADSs and our ordinary shares will be affected by the foreign exchange rates between U.S. dollars, HK dollars and the RMB. For example, to the extent that we need to convert U.S. dollars or HK dollars into RMB for our operations or if any of our arrangements with other parties are denominated in U.S. dollars or HK dollars and need to be converted into RMB, appreciation of the RMB against the U.S. dollar or the HK dollar would have an adverse effect on the RMB amount we receive from the conversion. Conversely, if we decide to convert RMB into U.S. dollars or HK dollars for the purpose of making payments for dividends on our ordinary shares or ADSs or for other business purposes, appreciation of the U.S. dollar or the HK dollar against the RMB would have a negative effect on the conversion amounts available to us.

Since 1983, the Hong Kong Monetary Authority (“HKMA”) has pegged the HK dollar to the U.S. dollar at the rate of approximately HK$7.80 to US$1.00. However, there is no assurance that the HK dollar will continue to be pegged to the U.S. dollar or that the HK dollar conversion rate will remain at HK$7.80 to US$1.00. If the HK dollar conversion rate against the U.S. dollar changes and the value of the HK dollar depreciates against the U.S. dollar, our assets denominated in HK dollars will be adversely affected. Additionally, if the HKMA were to repeg the HK dollar to, for example, the RMB rather than the U.S. dollar, or otherwise restrict the conversion of HK dollars into other currencies, then our assets denominated in HK dollars will be adversely affected.

### Credit Risk

Financial instruments that are potentially subject to significant concentration of credit risk consist of cash and cash equivalents, short-term investments, accounts receivable, and notes receivable.

The carrying amounts of cash and cash equivalents and short-term investments represent the maximum amount of loss due to credit risk. We had cash and cash equivalents of $680.8 million and $964.1 million and short-term investments of $575.3 million and $445.0 million as of June 30, 2022 and December 31, 2021, respectively. As of June 30, 2022 and December 31, 2021, all of our cash and cash equivalents and short-term investments were held by major financial institutions located in mainland China and international financial institutions outside of mainland China which we believe are of high credit quality and we continually monitor the credit worthiness of these financial institutions.

Accounts receivable are typically unsecured and are derived from product sales and collaborative arrangement. We manage credit risk of accounts receivable through ongoing monitoring of the outstanding balances and limit the amount of credit extended based upon payment history and the debtor’s current credit worthiness. Historically, we have collected the receivables from customers within the credit terms with no significant credit losses incurred. As of June 30, 2022, our two largest debtors accounted for approximately 35% of our total accounts receivable collectively.

Certain accounts receivable balances are settled in the form of notes receivable. As of June 30, 2022, such notes receivable included bank acceptance promissory notes that are non-interest bearing and due within six months. These notes receivable were used to collect the receivables based on an administrative convenience, given these notes are readily convertible to known amounts of cash. In accordance with the sales agreements, whether to use cash or bank acceptance promissory notes to settle the receivables is at our discretion, and this selection does not impact the agreed contractual purchase prices.

### Inflation

In recent years, mainland China has not experienced significant inflation and thus inflation has not had a material impact on our results of operations. Although we have not been materially affected by inflation in the past, we can provide no assurance that we will not be affected in the future by higher rates of inflation in mainland China.

## Controls and procedures

As filed, 1,810 characters.

### Management’s Evaluation of our Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in the reports that we file or submit under the Securities Exchange Act of 1934, as amended (the “Exchange Act”), is (1) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (2) accumulated and communicated to our management, including our principal executive officer and principal financial officer, to allow timely decisions regarding required disclosure.

As of June 30, 2022, our management, with the participation of our principal executive officer and principal financial officer, evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives, and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Our principal executive officer and principal financial officer have concluded based upon the evaluation described above that, as of June 30, 2022, our disclosure controls and procedures were effective at a reasonable assurance level.

### Changes in Internal Control over Financial Reporting

During the three months ended June 30, 2022, there have not been any changes in our internal controls over financial reporting (as such item is defined in Rules 13a-15(f) and 15d-15(f) promulgated under the Exchange Act) that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting.

## Risk factors

As filed, 12,444 characters.

This Quarterly Report on Form 10-Q should be read in conjunction with our 2021 Annual Report and Q1 2022 Form 10-Q, which describe various material risks and uncertainties to which we are or may become subject. These risks and uncertainties could, directly or indirectly, adversely affect our business, results of operations, financial condition, liquidity, or cash flows and could cause our actual results to differ materially from our past results or the results contemplated by any forward-looking statements we make. We believe the risks described in this section of our Quarterly Report on Form 10-Q and our 2021 Annual Report and Q1 2022 Form 10-Q are the most significant we face; however, these are not the only risks we face. We face additional risks and uncertainties not currently known to us or that we currently believe are not material.

Material changes from the risk factors set forth in our 2021 Annual Report and our Q1 2022 Form 10-Q are set forth below:

***We face risks related to the ongoing effects of the COVID-19 pandemic, including government actions and quarantine measures taken in response, particularly in mainland China where our operations are primarily located. For example, the COVID-19 pandemic has adversely affected our sales, marketing, development activities of our proprietary products and our licensor’s products, and our clinical trial operations, and it may continue to adversely affect our business and results of operations, perhaps significantly, depending on the nature, severity, and duration of the continuing effects of the pandemic.***

Since December 2019, global health concerns relating to the COVID-19 pandemic have been weighing on the macroeconomic environment and have significantly increased economic volatility and uncertainty. Government authorities worldwide, including in mainland China, have implemented numerous measures to try to contain the spread of the virus, such as travel bans and restrictions, quarantines, shelter-in-place or stay-at-home orders, and business shutdowns. Our business operations and those of our suppliers, CROs, CMOs, and other contractors and third parties on which we rely – as well as the Chinese economy more broadly – have been, and may continue to be, adversely affected by the effects of the pandemic and such government measures taken in response.

In the first quarter of 2022, there were a number of COVID-19 cases in Greater China, especially in some large cities like Shanghai, where one of our principal executive offices is located, that experienced a wave of intermittent government shutdowns in connection with COVID-19 control measures, especially between March and May 2022 when COVID-19 lockdown restrictions increased and most of the city was subject to a full lockdown. Other cities or regions in Greater China are, have been, or may be subject to similar government restrictions or lockdowns as a result of continued uncertainties associated with, and future developments of, the pandemic. The effects of the COVID-19 pandemic and restrictive quarantine measures imposed by the Chinese government in response have adversely affected our business, and may continue to adversely affect our business, perhaps significantly, for the remainder of this fiscal year and beyond, depending on the nature, severity, and duration of the ongoing effects of the COVID-19 pandemic, particularly in mainland China where our operations are primarily located.

Specifically, the COVID-19 pandemic has adversely impacted our operations, business, and financial results, including our manufacturing and supply chain, our and our partners’ sales, marketing, and clinical trial operations, and our ability to advance our research and development activities and pursue the development of our pipeline products. For example, due to service interruptions to hospitals and treatment centers in mainland China arising in connection with the outbreak of COVID-19, some patients have experienced difficulties in accessing hospital care and, as a result, they have had limited or no access to ZEJULA, Optune, QINLOCK, or NUZYRA. The ability to conduct in-person interactions between medical representatives and physicians has also been adversely affected. Decreased access to our products has an adverse effect on our revenue. We expect the majority of the impact on our revenue from the lockdown measures in mainland China from March 2022 to May 2022 to be reflected in our results for the second half of 2022. In addition, we have experienced delays in the enrollment of patients in our clinical trials due to outbreaks of COVID-19 where we are conducting such trials. Our commercial partners and licensors also have similarly experienced delays in enrollment of patients to their clinical trials due to outbreaks of COVID-19 in their respective territories. Although so far none of our

NDA submissions and acceptances, key clinical development milestones, or clinical trial application approvals have been materially delayed, there is no guarantee this will continue to be the case.

Additionally, the COVID-19 government restrictions and shutdown orders – those currently in effect and those which may be imposed in the future – may cause us or our commercial partners, licensors, and CMOs to experience delays or interruptions in the ability to manufacture and supply the products we are selling commercially in Greater China. For example, if COVID-related restrictions in Shanghai resume or are enhanced, such restrictions may impact the distribution and sale of our products within Greater China. These and other government restrictions may limit our and our distributors’ ability to successfully sell our commercial products in Greater China, even if we implement contingency plans. Any or all of these adverse effects arising from COVID-19 may adversely affect our business and results of operations this year, and perhaps beyond, or cause the value of the Company to decline, potentially limiting our ability to obtain additional financing on terms acceptable to the Company.

COVID-19 government restrictions and lockdown orders, including those requiring our employees to work from their homes or preventing our executives from traveling to or from mainland China, Hong Kong, and the United States, could also negatively affect our business, such as through absenteeism or employee turnover, other operational disruptions, or increased risk of a cybersecurity incident.

There are no comparable recent events that provide guidance as to the effect the COVID-19 outbreak as a global pandemic may have and, as a result, the ultimate impact of the pandemic is highly uncertain and subject to change, and the actual effects on our business and results of operations will depend on many factors beyond our control.

***We may be subject to additional approval, filing, and compliance obligations with Chinese authorities in connection with our engagement of KPMG, a U.S. auditor that is subject to PCAOB inspection.***

Pursuant to the revised Provisions on Strengthening Confidentiality and Archives Administration of Overseas Securities Offering and Listing by Domestic Companies (Draft for Comments), released by the CSRC for public comment on April 2, 2022 (the “Draft Archives Rules”), where Chinese domestic companies (including Chinese domestic companies that are listed outside of mainland China through a overseas holding entity, such as Zai Lab Limited) seek to disclose or provide, or disclose or provide through its overseas holding entity, documents and materials that have a sensitive impact (i.e., be detrimental to national security or the public interest if divulged) or contain state secrets or government department work secrets to relevant entities or individuals including securities companies, other securities service providers and overseas regulators in connection with a securities offering outside of mainland China, such company will be required to complete the relevant approval, filing, and other regulatory procedures. Disclosure of such materials to auditors based outside of mainland China is explicitly included within the scope of the Draft Archives Rules, and any such auditors are required under Chinese law to abide by the corresponding approval, filing, and compliance procedures in accordance with relevant Chinese regulations. The Draft Archives Rules are still in draft form, and we do not yet know the scope of materials that have a sensitive impact or contain state secrets or government department work secrets, but if the Draft Archives Rules become effective and our auditor’s work papers are determined to be materials that have a sensitive impact or contain state secrets or government department work secrets, our engagement of KPMG may subject us and KPMG to additional approval, filing, and compliance obligations in mainland China under the Draft Archives Rules.

***Our business and financial results, including our clinical development, our ability to raise capital or raise capital on favorable terms, and the market price of our ordinary shares and/or our ADSs, may be adversely affected by Russia’s invasion of Ukraine, such as due to delays in certain partnered studies or as a result of imposed or threatened sanctions on China, Chinese banks, or companies with operations in China or heightened tensions between the United States and China as a result of actions taking in response to this war.***

Although our business and financial results have not yet been adversely affected by the war in Ukraine, and we do not conduct business in Russia or Ukraine, our business and financial results, including our development programs, our ability to raise capital or raise capital on favorable terms, and the market price of our ordinary shares and/or our ADSs, may be adversely affected by Russia’s invasion of Ukraine. For example, there have been, and may continue to be, delays in certain partnered studies. In addition, the United States and other nations have raised the possibility of sanctions on China, Chinese banks, and companies with operations in China that do business with Russia or its allies, including Belarus. Although we do not conduct business in Russia or Belarus, or with Russian or Belarusian counterparties, we may be impacted by sanctions imposed on third parties with which we do business, such as customers, suppliers, intermediaries, services providers, or banks. Our business and operations may also be adversely impacted by any actions taken by China in response to the war or any related sanctions or threatened sanctions. Such actual or threatened sanctions and other geopolitical factors arising in connection with the way, such as continued political or economic instability or increased economic or political tensions between the United States and China, could also adversely affect our business and financial results, including our ability to raise capital or raise capital on favorable terms and the market price of our ordinary shares and/or our ADSs.

***Our results of operations may be adversely impacted in the event of a sustained period of increased inflation.***

The global economy, including the U.S. economy, has experienced rising inflation in recent quarters. Increased inflation may have an adverse impact on our expenses and, as a result, our results of operations. We source key materials from third parties located in the United States, either directly through agreements with suppliers or indirectly through our manufacturers who have agreements with suppliers, as well as through our licensors. For example, we rely on Turning Point to manufacture and supply TPX-0022 and repotrectinib (TPX-0005), argenx to manufacture and supply efgartigimod, MacroGenics to manufacture and supply margetuximab, tebotelimab and a pre-clinical multi-specific TRIDENT molecule, Entasis to manufacture and supply SUL-DUR, Novocure to manufacture and supply Optune, Deciphera to manufacture and supply QINLOCK, Incyte to manufacture and supply retifanlimab (INCMGA0012 (PD-1)), Regeneron to manufacture and supply odronextamab, Mirati to manufacture and supply adagrasib, and Blueprint to manufacture and supply BLU-701 and BLU-945. Sustained or rising inflation may result in increased cost to us in obtaining supplies of our products and product candidates, or key materials relating thereto. As a result, our results of operations may be adversely impacted.

Filed Aug 9, 2022.
Source: SEC EDGAR, the filing index for accession 0001628280-22-021975. Last ingested by Listed: Nov 15, 2026, 00:47 ET. No prices; not investment advice.
